Compare iShares Global Clean Energy ETF (ICLN) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Clean Energy ETF vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? iShares Global Clean Energy ETF trades at $16.43 (market cap $2.13B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: iShares Global Clean Energy ETF is far larger — about 2.2× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, iShares Global Clean Energy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Global Clean Energy ETF for 88 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| ICLN | MRVI | |
|---|---|---|
Market Cap | $2.13B | $977.37M |
Volume | 5,190,061 | 2,742,564 |
52-Week High | $23.75 | $9.00 |
52-Week Low | $16.00 | $2.83 |
Typical Hold Time | 88 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICLN trades at $17.18 with a slight 0.35% daily gain, though technical indicators signal bearish momentum with 15 sell signals versus 1 buy. The ETF faces headwinds from higher expense ratios and volatility compared to traditional energy peers, with recent news highlighting underperformance against fossil fuel ETFs. Support and resistance cluster tightly around $17, indicating potential consolidation.
Outlook remains cautious due to weak technicals and competitive pressure from lower-cost energy ETFs. Long-term growth hinges on renewable energy adoption, but near-term risks include fee disadvantages and sector volatility. Investors should weigh clean energy exposure against more stable traditional energy alternatives.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
